^
    1m
    A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=143, Recruiting, Akesobio Australia Pty Ltd | Phase classification: P1a/1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    Kaitanni (cadonilimab) • AK127
    10ms
    A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=216, Not yet recruiting, Akeso
    New P1/2 trial
    |
    ivonescimab (AK112) • AK127
    12ms
    A Study of AK127 Combined With AK104 in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1a/1b, N=205, Not yet recruiting, Akeso
    New P1 trial • Combination therapy • Metastases
    |
    Kaitanni (cadonilimab) • AK127